Notable Labs Company Description
Notable Labs, Ltd., a clinical-stage platform therapeutics company, develops predictive medicines for patients with cancer.
The company, through its proprietary Predictive Medicines Platform (PMP), bio-simulates a patient’s cancer treatment and predicts whether patient will clinically respond to their actual treatment.
Its PMP is designed to identify and select patients expected to be clinically responsive prior to the initiation of their treatment and enable fast-track therapeutic development in this patient population.
The company’s lead product is Volasertib, a polo like kinase 1 inhibitor to induce cell cycle arrest and apoptosis in various cancer cells.
It is also developing two candidate predictive medicines and clinical-stage candidates for development in platform-predicted responders with acute myeloid leukemia.
The company is based in Foster City, California. On October 13, 2024, Notable Labs, Ltd. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.
| Country | Israel |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 16 |
| CEO | Kaile Zagger |
Contact Details
Address: 320 Hatch Drive Foster City, 94404 United States | |
| Phone | 415 851 2410 |
| Website | notablelabs.com |
Stock Details
| Ticker Symbol | NTBLQ |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | IL0012002452 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Kaile Zagger | Interim Chief Executive Officer and Chief Restructuring Officer |
| Scott Alan McPherson CFE, CPA, CVA | Chief Financial Officer |
| Dr. Joseph P. Wagner Ph.D. | Chief Scientific Officer |
| Dr. Glenn C. Michelson M.D. | Chief Medical Officer |